Optimizing Deep Brain Stimulation Programming in Parkinson’s Disease

  • Fiona GuptaEmail author
  • Punit Agrawal


The success of deep brain stimulation (DBS) therapy in Parkinson’s disease (PD), whether the target is subthalamic nucleus (STN), globus pallidus interna (GPi), or ventral intermediate thalamus (VIM), starts prior to DBS surgery. The route to best outcomes is based on the proper screening and patient selection, followed by identifying expected clinical benefits and setting the stage with the patient for realistic expectations for goals of DBS therapy. Important information to obtain prior to proceeding with DBS therapy include: Presence of tremor and response to PD medication; Amount (hours/minutes) and severity of medication off time with respect to doses of medication, and specific motor symptoms (tremor, rigidity, bradykinesia), with localization to side and part of the body; History and details of gait changes with medication wearing off, or if present at peak, response to medications; Dyskinesia as it relates to medications: peak effect, presence when medication worn off (such as upon awakening, prior to first morning dose of PD medications), or biphasic with respect to medication onset of action and wearing off; Motor score in relationship to best response to medication off/on in a person experiencing motor fluctuations; History of levodopa intolerance. These same issues are often useful to reassess at the first visit after DBS therapy has been initiated and kept in mind subsequently, to help identify potential for further improvement with adjustments in DBS parameters and help achieve stimulation optimization.


  1. 1.
    Rizzone M, et al. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: effects of variation in stimulation parameters. J Neurol Neurosurg Psychiatry. 2001;71:215–9.CrossRefGoogle Scholar
  2. 2.
    Moro E, et al. The impact on Parkinson’s disease of electrical parameter settings in STN stimulation. Neurology. 2002;59:706–13.CrossRefGoogle Scholar
  3. 3.
    Dayal V, et al. Subthalamic nucleus deep brain stimulation in Parkinson’s disease: the effect of varying stimulation parameters. J Parkinsons Dis. 2017;7:235–45.CrossRefGoogle Scholar
  4. 4.
    Limousin P, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345:91–5.CrossRefGoogle Scholar
  5. 5.
    Timmerman L, et al. Ten hertz stimulation of the subthalamic nucleus deteriorates motor symptoms in Parkinson’s disease. Mov Disord. 2004;19:1328–33.CrossRefGoogle Scholar
  6. 6.
    Limousin P, et al. Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients. Mov Disord. 1996;11:231–5.CrossRefGoogle Scholar
  7. 7.
    McIntyre C, et al. Cellular effects of deep brain stimulation: model-based analysis of activation and inhibition. J Neurophysiol. 2004;91:1457–69.CrossRefGoogle Scholar
  8. 8.
    Ranck J. Which elements are excited in electrical stimulation of mammalian central nervous system: a review. Brain Res. 1975;98:417–40.CrossRefGoogle Scholar
  9. 9.
    Krack P, et al. Postoperative management of subthalamic nucleus stimulation for Parkinson’s disease. Mov Disord. 2002;17(Suppl. 3):S188–97.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of NeurologyThe Mount Sinai HospitalNew YorkUSA
  2. 2.Department of Neurology and Center for NeuromodulationThe Ohio State University Wexner Medical CenterColumbusUSA

Personalised recommendations